New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review

Abstract

Uveal melanoma (UM) is a rare disease, but the most common primary intraocular cancer, mostly localized in the choroid. Currently, the first-line treatment options for UM are radiation therapy, resection, and enucleation. However, although these treatments could potentially be curative, half of all patients will develop metastatic disease, whose prognosis is still poor. Indeed, effective therapeutic options for patients with advanced or metastatic disease are still lacking. Recently, the development of new treatment modalities with a lower incidence of adverse events, a better disease control rate, and new therapeutic approaches, have merged as new potential and promising therapeutic strategies. Additionally, several clinical trials are ongoing to find new therapeutic options, mainly for those with metastatic disease. Many interventions are still in the preliminary phases of clinical development, being investigated in phase I trial or phase I/II. The success of these trials could be crucial for changing the prognosis of patients with advanced/metastatic UM. In this systematic review, we analyzed all emerging and available literature on the new perspectives in the treatment of UM and patient outcomes; furthermore, their current limitations and more common adverse events are summarized.

Differences between Mycobacterium chimaera and tuberculosis Using Ocular Multimodal Imaging: A Systematic Review

“…The search workflow was designed in adherence to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and according previous reports [ 14 , 15 , 16 , 17 , 19 , 20 ].…”

Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries

“…A new drug (and/or an old drug for new indications) requires the authorization from a regulatory authority to be marketed (van Nooten et al, 2012;Gozzo et al, 2020a;Drago et al, 2020;Gozzo et al, 2021a;Toro et al, 2021). Moreover, price and reimbursement procedures need to be performed by competent authorities to find an agreement between companies and payers for market access (Gozzo et al, 2021a).…”

“De novo” Appearance of a Choroidal Melanoma During 5 Yearsʼ Follow-up for CHRPE

“…Uveal melanoma, the most common primary intraocular malignancy in adults, has an incidence of about 6 new cases per million per year in Caucasians 1 , 2 . The choroid is the most frequent localization (85 – 91%), whereas the ciliary body or the iris are affected in only 9 – 15% of cases.…”

“…Relative risk factors are a fair skin, light eye color, ocular or oculodermal melanocytosis, and the presence of a cutaneous, iris, or choroidal nevus. It is associated with BAP1 or BRCA1 mutation carriers [2].…”